Investigations
DexCom, Inc.
Overview
Overview
- Deadline:
- Oct 21, 2024
| Company Name: | Company Name: DexCom, Inc. |
| Stock Symbol: | Stock Symbol: DXCM |
DexCom, Inc. (NASDAQ: DXCM): DexCom (“DexCom” or the “Company”) has been sued for violations of the federal securities laws. The complaint asserts claims against the Company and certain of its senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in DexCom securities between January 8, 2024 to July 25, 2024, inclusive. The case is pending in the U.S. District Court for the Southern District of California and is captioned Alonzo v. DexCom, Inc., No. 24-cv-01485.
If you incurred losses on your investments in DexCom, you are encouraged to submit your information.
Why was DexCom Sued for Securities Fraud?
DexCom develops glucose monitoring systems for diabetes management. The complaint alleges that during the relevant period, DexCom misrepresented its ability to capitalize on its growth potential to reach the projected record number of new patients and simultaneously outpace the prior fiscal year’s gross margins, while scaling customer conversion to the new G7 platform.
As alleged, these statements were materially false and misleading. In truth, DexCom was unable to book new customers and its revenue per customer had plummeted. BFA is also investigating whether the company misrepresented the impact GLP-1 weight loss drugs were having on DexCom’s business.
The Stock Declines as the Truth is Revealed
After the market closed on July 25, 2024, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. The company attributed the results to challenges it had encountered restructuring its sales force. This news caused the price of DexCom stock to decline by $41.25 per share, or over 38%, to close at $107.85 per share on July 25, 2024.
What are my Rights?
If you purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive, you may ask the Court no later than October 21, 2024, which is the first business day after 60 days from the date of the publication of notice of pendency of the action, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
If you incurred losses on your investments in DexCom, you are encouraged to submit your information.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
If you incurred losses on your investments in DexCom, you are encouraged to submit your information.
Why was DexCom Sued for Securities Fraud?
DexCom develops glucose monitoring systems for diabetes management. The complaint alleges that during the relevant period, DexCom misrepresented its ability to capitalize on its growth potential to reach the projected record number of new patients and simultaneously outpace the prior fiscal year’s gross margins, while scaling customer conversion to the new G7 platform.
As alleged, these statements were materially false and misleading. In truth, DexCom was unable to book new customers and its revenue per customer had plummeted. BFA is also investigating whether the company misrepresented the impact GLP-1 weight loss drugs were having on DexCom’s business.
The Stock Declines as the Truth is Revealed
After the market closed on July 25, 2024, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. The company attributed the results to challenges it had encountered restructuring its sales force. This news caused the price of DexCom stock to decline by $41.25 per share, or over 38%, to close at $107.85 per share on July 25, 2024.
What are my Rights?
If you purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive, you may ask the Court no later than October 21, 2024, which is the first business day after 60 days from the date of the publication of notice of pendency of the action, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
If you incurred losses on your investments in DexCom, you are encouraged to submit your information.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.